Thermo Fisher’s acquisition of Brammer Bio draws attention to the growing role of viral vectors across the gene therapy landscape. We look at financing and market trends for the viral vector manufacturing market.
On March 25th, Thermo Fisher Scientific acquired Brammer Bio — a biologics manufacturing company that develops viral vectors for cell and gene therapies. This acquisition by the medical tech incumbent strengthens its pharma services business — a unit that saw its last acquisition back in May 2017 with Patheon.
We take a look at the Brammer Bio transaction to understand:
- Transaction rationale, comparable M&A transactions, and valuations
- The broader viral vector manufacturing market landscape & market size
- Competitors & substitutes to Brammer Bio
- Other potential acquirers in the space